Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D'Hondt V, De Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart M, Awada A. Ignatiadis M, et al. Among authors: veys i. PLoS One. 2016 Jul 25;11(7):e0154009. doi: 10.1371/journal.pone.0154009. eCollection 2016. PLoS One. 2016. PMID: 27454930 Free PMC article. Clinical Trial.
ICG-fluorescence imaging for detection of peritoneal metastases and residual tumoral scars in locally advanced ovarian cancer: A pilot study.
Veys I, Pop FC, Vankerckhove S, Barbieux R, Chintinne M, Moreau M, Nogaret JM, Larsimont D, Donckier V, Bourgeois P, Liberale G; Group R&D for the Clinical Application of Fluorescence Imaging of the Jules Bordet Institute. Veys I, et al. J Surg Oncol. 2018 Feb;117(2):228-235. doi: 10.1002/jso.24807. Epub 2017 Aug 8. J Surg Oncol. 2018. PMID: 28787759
Absence of residual fluorescence in the surgical bed at near-infrared fluorescence imaging predicts negative margins at final pathology in patients treated with breast-conserving surgery for breast cancer.
Pop FC, Veys I, Vankerckhove S, Barbieux R, Chintinne M, Moreau M, Donckier V, Larsimont D, Bourgeois P, Liberale G. Pop FC, et al. Among authors: veys i. Eur J Surg Oncol. 2021 Feb;47(2):269-275. doi: 10.1016/j.ejso.2020.09.036. Epub 2020 Oct 13. Eur J Surg Oncol. 2021. PMID: 33183928 Clinical Trial.
61 results